Artificial intelligence (AI) has been one of the largest disruptors in drug development over the past few years, with the promise of innovation and greater efficiencies keeping the pharma industry heavily invested. There have been major advancements in AI-discovered molecules and AI-powered platforms for decentralized treatment, in addition to many more AI applications that have changed the game when it comes to drug R&D operations and strategy.
As life science organizations shift away from the early days of AI adoption, we enter a critical period of transformation that requires specialized expertise and collaboration in order to safely and strategically integrate AI into established drug development workflows. This type of global integration not only necessitates a patient-centric approach, but also a deep understanding of drug R&D stakeholders’ needs.
To evaluate those needs, Norstella conducted its inaugural industry-wide survey in August 2024, which gathered insights into current and expected AI trends within the pharma R&D sector. The 125 survey respondents represent a diverse sample of senior decision-makers from pharma organizations around the world. The following industry report highlights the main findings from this research and how Norstella’s data-driven capabilities can help navigate the ever-changing drug development landscape.
Read more about the survey’s findings in the following report.
Learn more about NorstellaLinQ today.
We’re looking for agile, growth-oriented team players who are passionate about client success and helping clients bring life-saving therapies to market quicker—and help patients in need.
Work with usHave questions about Norstella or its brands? Or do you want to know more about how to solve your challenges at each stage of the drug life cycle?
We want to hear from you